Stupp R, Mason WP, Bent van den MJ, et al: Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005, 352: 987-996. 10.1056/NEJMoa043330.
Article
CAS
PubMed
Google Scholar
Wong ET, Hess KR, Gleason MJ, et al: Outcomes and prognostic factors in recurrent glioma patients enrolled onto phase II clinical trials. J Clin Oncol. 1999, 17: 2572-2578.
CAS
PubMed
Google Scholar
Ammirati M, Galicich JH, Arbit E, et al: Reoperation in the treatment of recurrent intracranial malignant gliomas. Neurosurgery. 1987, 21: 607-614.
Article
CAS
PubMed
Google Scholar
Choucair AK, Levin VA, Gutin PH, et al: Development of multiple lesions during radiation therapy and chemotherapy in patients with gliomas. J Neurosurg. 1986, 65: 654-658. 10.3171/jns.1986.65.5.0654.
Article
CAS
PubMed
Google Scholar
Brandes AA, Fiorentino M: How effective is BCNU in recurrent glioblastoma in the modern era? A phase II trial. Neurology. 2004, 63: 1281-4.
Article
CAS
PubMed
Google Scholar
Zhang M, Chakravarti A: Novel radiation-enhancing agents in malignant gliomas. Semin Radiat Oncol. 2006, 16: 29-37. 10.1016/j.semradonc.2005.08.004.
Article
CAS
PubMed
Google Scholar
Kirches E, Scherlach C, von Bossanyi P, Schneider T, Szibor R, Kutz E, Warich-Kirches M, Dietzmann K: MGMT- and P430 3A-inhibitors do not sensitize glioblastoma cell cultures against nitrosoureas. Clin Neuropathol. 1999, 18: 1-8.
CAS
PubMed
Google Scholar
MacDonald DR, Cascino TL, Schold SC, Cairncross JG: Response criteria for phase II studies of supratentorial malignant glioma. J Clin Oncol. 1990, 8: 1277-1280.
CAS
PubMed
Google Scholar
Norden AD, Young GS, Setayesh K, Muzikansky A, Klufas R, Ross GL, Ciampa AS, Ebbeling LG, Levy B, Drappatz J, Kesari S, Wen PY: Bevacizumab for recurrent malignant gliomas: efficacy, toxicity, and patterns of recurrence. Neurology. 70: 779-787. 10.1212/01.wnl.0000304121.57857.38.
Sampath P, Sungarian A, Alderson L, et al: BCNU-impregnated wafers (Gliadel) plus irinotecan (Camptosar) in combination treatment for patients with recurrent glioblastoma multiforme [abstract]. Annual Meeting of the Congress of Neurological Surgeons, Boston, MA. 2005
Google Scholar
Hou LC, Veeravagu A, Hsu AR, Tse VCK: Recurrent glioblastoma multiforme: a review of natural history and management options. Neurosurg Focus. 2006, 20: E5-10.3171/foc.2006.20.4.2.
Article
PubMed
Google Scholar
Brem H, Piantadosi S, Burger PC, et al: Placebo-controlled trial of safety and efficacy of intraoperative controlled delivery by biodegradable polymers of chemotherapy for recurrent glioblastomas. The Polymer-brain Tumor Treatment Group. Lancet. 1995, 345: 1008-1012. 10.1016/S0140-6736(95)90755-6.
Article
CAS
PubMed
Google Scholar
Combs SE, Widmer V, Thilmann C: Stereotactic radiosurgery (SRS). Treatment options for recurrent glioblastoma multiforme (GBM). Cancer. 2005, 104: 2168-2173. 10.1002/cncr.21429.
Article
PubMed
Google Scholar
Mahajan A, McCutcheon IE, Suki D: Case-control study of stereotactic radiosurgery for recurrent glioblastoma multiforme. J Neurosurg. 2005, 103: 210-217. 10.3171/jns.2005.103.2.0210.
Article
PubMed
Google Scholar
Shrieve DC, Alexander E, Wen PY, et al: Comparison of stereotactic radiosurgery and brachytherapy in the treatment of recurrent glioblastoma multiforme. Neurosurgery. 1995, 36: 275-284. 10.1097/00006123-199502000-00006.
Article
CAS
PubMed
Google Scholar
Chan TA, Weingart JD, Parisi M, et al: Treatment of recurrent glioblastoma multiforme with GliaSite brachytherapy. Int J Radiat Oncol Biol Phys. 2005, 62: 1133-1139.
Article
PubMed
Google Scholar
Scharfen CO, Sneed PK, Wara WM, et al: High activity iodine-125 interstitial implant for gliomas. Int J Radiat Oncol Biol Phys. 1992, 24: 583-591.
Article
CAS
PubMed
Google Scholar
Chamberlain MC, Kormanik PA: Practical guidelines for the treatment of malignant gliomas. West J Med. 1998, 168: 114-120.
CAS
PubMed
PubMed Central
Google Scholar
Stewart LA: Chemotherapy in adult high-grade glioma: a systematic review and meta-analysis of individual patient data from 12 randomised trials. Lancet. 2002, 359: 1011-1018. 10.1016/S0140-6736(02)08091-1.
Article
CAS
PubMed
Google Scholar
Wick W, Steinbach JP, Küker WM, et al: One week on/one week off: a novel active regimen of temozolomide fro recurrent glioblastoma. Neurology. 2004, 62: 2113-2115.
Article
CAS
PubMed
Google Scholar
Vredenburgh JJ, Desjardins A, Herndon JE, Marcello J, Reardon DA, Quinn JA, Rich JN, Sathornsumetee S, Gururangan S, Sampson J, Wagner M, Bailey L, Bigner DD, Friedman AH, Friedman HS: Bevacizumab plus irinotecan in recurrent glioblastoma multiforme. J Clin Oncol. 2007, 25: 4722-9. 10.1200/JCO.2007.12.2440.
Article
CAS
PubMed
Google Scholar
Brandes AA, Tosoni A, Amistà P, Nicolardi L, Grosso RN, Berti F, Ermani M: How effective is BCNU in recurrent glioblastoma in the modern era? A phase II trial. Neurology. 2004, 63: 1281-1284.
Article
CAS
PubMed
Google Scholar
Brandsma D, Stalpers L, Taal W, Sminia P, Bent van den MJ: Clinical features, mechanisms, and management of pseudoprogression in malignant gliomas. Lancet Oncol. 2008, 9: 453-61. 10.1016/S1470-2045(08)70125-6.
Article
PubMed
Google Scholar
Liu L, Gerson SL: Targeted modulation of MGMT: Clinical implications. Clin Cancer Res. 2006, 12: 328-331. 10.1158/1078-0432.CCR-05-2543.
Article
CAS
PubMed
Google Scholar
Hegi ME, Diserens AC, Gorlia T, Hamou MF, de Tribolet N, Weller M, Kros JM, Hainfellner JA, Mason W, Mariani L, Bromberg JE, Hau P, Mirimanoff RO, Caincross JG, Janzer RC, Stupp R: MGMT gene silencing and benefit from temozolomide in GBM. N Engl J Med. 2005, 352: 997-1003. 10.1056/NEJMoa043331.
Article
CAS
PubMed
Google Scholar
Silvani A, Gaviani P, Lamperti EA, Eoli M, Falcone C, DiMeco F, Milanesi IM, Erbetta A, Boiardi A, Fariselli L, Salmaggi A: Cisplatinum and BCNU chemotherapy in primary glioblastoma patients. J Neurooncol. 2009,
Google Scholar
Schold S, et al: O6-Alkylguanine-DNA alkytransferase and sensitivity to procarbazine in human braintumor xenografts. J Neurosurg. 1989, 70: 573-7. 10.3171/jns.1989.70.4.0573.
Article
PubMed
Google Scholar
Yarosh DB: The role of O6-methylguanine-DNA methyl-transferase in cell survival, mutagenesis, and carcinogenesis. Mutat Res. 1985, 145: 1-16.
CAS
PubMed
Google Scholar
Dolan ME, Moschel RC, Pegg AE: Depletion of mammalian O6-alkylguanine-DNA alkyltransferase activity by O6-benzylguanine provides a means to evaluate the role of this protein in protection against carcinogenic and therapeutic alkylating agents. Proc Natl Acad Sci USA. 1990, 87: 5368-72. 10.1073/pnas.87.14.5368.
Article
CAS
PubMed
PubMed Central
Google Scholar
Stummer W, Pichlmeier U, Meinel T, Wiestler OD, Zanella F, Reulen HJ: Fluorescence-guided surgery with 5-amino-levulinic acid for resection of malignant glioma: a randomised controlled multicentre phase III trial. Lancet Oncol. 2006, 7: 392-401. 10.1016/S1470-2045(06)70665-9.
Article
CAS
PubMed
Google Scholar
Lacroix M, Abi-Said D, Fourney DR, et al: A multivariate analysis of 416 patients with glioblastoma multiforme: prognosis extent of resection, and survival. J Neurosurg. 2001, 95: 190-198. 10.3171/jns.2001.95.2.0190.
Article
CAS
PubMed
Google Scholar
Shinoda J, Sakai N, Murase S, Yano H, Matsuhisa T, Funakoshi T: Selection of eligible patients with supratentorial glioblastoma multiforme for gross total resection. J Neurooncol. 2001, 52: 161-171. 10.1023/A:1010624504311.
Article
CAS
PubMed
Google Scholar